Key Market Overview:
Circulating tumor cells market size was worth over USD 3.89 Billion in 2022 and is estimated to reach over USD 9.85 Billion by 2030, growing at a CAGR of 12.3% during the forecast period (2023-2030).
Circulating tumor cells (CTCs) are cells that have detached from a primary tumor and enter the bloodstream, lymphatic system, or other bodily fluids. The cells are shed by the primary tumor and are transported to other organs or tissues for the formation of secondary tumors which is referred to as a process known as metastasis. The presence of CTCs in the blood act as an indication of cancer, and their analysis is useful for diagnosis, monitoring of disease progression, and treatment response. Thus, CTCs are analyzed for prognostic value due to the presence and number of CTCs in the blood have been associated with poor clinical outcomes.
The presence of such CTCs in the bloodstream is considered a rare phenomenon, which results in challenging detection and isolation of such cells. Typically, such CTCs are distinguished from other circulating cells based on physical and biological properties such as size, shape, and expression of specific biomarkers. Several methods have been developed to isolate and characterize CTCs such as immunomagnetic separation, microfluidic-based technologies, and flow cytometry.
Moreover, the analysis of CTCs is considered as a non-invasive diagnostic tool for cancer. Such analysis offers information on the aggressiveness and stage of the disease and also helps to identify potential therapeutic targets. The detection and separation of such CTCs play a crucial role in detecting cancer at early stages. For instance, according to the World Health Organization (WHO), cancer is one of the leading causes of death globally, with an estimated 10 million deaths in 2020. Thus, the increased prevalence of cancer among population is anticipated to boost the demand for CTCs which are used to monitor the response to treatment and the development of drug resistance.
Circulating tumor cells Market Coverage
|Report Attributes||Report Details|
|Market Size in 2030 (USD Billion)||9.85 Billion|
|CAGR (2023-2030)||12.3 %|
|By Technology||CTC Detection And Enrichment Methods (Immunocapture (Label-Based) (Negative Enrichment, Positive Enrichment), Size-Based Separation (Label-Free) (Membrane-Based, Microfluidic-Based), Density-Based Separation (Label-Free), Combined Methods (Label-Free), Others) CTC Detection Methods (SERS, Microscopy, Others), CTC Analysis|
|By Specimen||Blood, Bone Marrow, Other Body Fluids|
|By Product||Kits & Reagents, Blood Collection Tubes, Devices or Systems|
|By Application||Clinical/ Liquid Biopsy (Risk Assessment, Screening, and Monitoring), Research (Cancer Stem Cell & Tumorogenesis Research, Drug/Therapy Development)|
|By End Use||Hospital and Clinics, Diagnostic Centers, Research and Academic Institutes, Others|
|By Geography||Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia] |
Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey]
North America [United States, Canada, Mexico]
Middle East & Africa [GCC, North Africa, South Africa]
South America [Brazil, Argentina, Columbia, Chile, Peru]
|Key Players||Fluxion Biosciences Inc., Bio-Techne, Precision Medicine Group, LLC., QIAGEN, Aviva Systems Biology Corporation, BIOCEPT, Inc., Thermo Fisher Scientific, Greiner Bio One International GmbH, Ikonisys Inc., Miltenyi Biotec, IVDiagnostics, BioFluidica, Canopus Bioscience Ltd., Biolidics Limited, Creativ MicroTech, Inc., LungLife AI, Inc., Epic Sciences, Rarecells Diagnostics, ScreenCell, Menarini Silicon Biosystems, LineaRx, Inc. (Vitatex, Inc.), Sysmex Corporation, STEMCELL Technologies, Inc. Cynvenio Biosystems|
The rising prevalence of cancer fueled an increase in the demand for non-invasive diagnostic tools such as CTC analysis that help in early detection, treatment selection, and disease monitoring. Moreover, recent advances in microfluidic-based technologies, immunomagnetic separation, and molecular assays also boost the market growth in terms of more efficient and sensitive methods of CTC isolation and characterization for improved accuracy and reliability of CTC analysis of diseases. Furthermore, the rising focus on personalized medicine and targeted therapies also accelerates the CTCs market due to offered information on specific biomarkers by CTC analysis which is targeted by personalized therapies to improve treatment outcomes and reduce the risk of adverse effects.
The high costs of CTC materials, drugs, and equipment mainly limit the market growth due to restricted access among most developing countries such as Brazil, Mexico, and Thailand. Moreover, the limited clinical validation of CTC utility hampers the market demand in large-scale clinical trials due to the need to establish the clinical significance of CTCs in various cancer types and stages. Further, the lack of standardization of CTC analysis, including the methods of isolation, detection, and characterization also limits the widespread adoption of CTC analysis in clinical practice.
The emergence of CTC analysis as a non-invasive alternative to conventional tissue biopsies that are painful and carry a risk of complications is expected to offer lucrative opportunities for CTC analysis as a patient-friendly approach with the process of a simple blood sample. Further, the scope of informing cancer research and drug development by CTC is also anticipated to create opportunities for market expansion in terms of the development of effective cancer therapies.
Circulating tumor cells Market Segmentation:
The technology segment is divided into CTC detection and enrichment methods, CTC Detection methods, and CTC analysis. The CTC detection and enrichment methods segment accounted for the largest market share over 69.7% in 2022. The segment is further sub-segmented into immunocapture (label-based), size-based separation (label-free), density-based separation (label-free), combined methods (label-free), and others. The high demand for CTC detection methods to identify the presence of cancer cells in the blood and the detection of a solid tumor by imaging methods supports segmental growth. Further, the large-scale usage of enrichment methods to isolate CTCs from the blood and provide CTC analysis in terms of information about the characteristics of cancer fuels the segment demand for understanding the aggressiveness and likelihood of metastasis.
The specimen segment is separated into blood, bone marrow, and other body fluids. The blood segment contributed the largest circulating tumor cells market share over 49.3% in 2022. The high dependence on blood specimens to analyze the molecular and genetic characteristics of CTCs supports segment growth in terms of access to information about the potential for metastasis and prediction of patient outcomes. Also, the bone marrow segment is anticipated to contribute significant shares to the market growth during the forecast period. The growing usage of bone marrow biopsy for detecting the presence of CTCs and confirming the diagnosis of cancer is expected to support segmental growth in cases with unknown primary tumors or difficulties in obtaining a biopsy from the primary tumor.
The application segment is categorized into clinical/ liquid biopsy and research. The research segment contributed the largest shares over 75.6% to the circulating tumor cells market growth in 2022. The research segment is further sub-segmented into cancer stem cell & tumorogenesis research, and drug/therapy development. Research in CTCs is also advancing the development of personalized cancer treatments. The increased need of analyzing the genetic makeup of CTCs by researchers to identify specific mutations and genetic changes that are present in individual tumors supports the demand for research in CTC. Such increased demand is due to the overall access to information among researchers for the selection of the most effective treatment alternatives for a patient and monitoring treatment response. Moreover, the clinical/ liquid biopsy segment is also anticipated to contribute substantial shares to the market growth during the forecast period due to high demand as a non-invasive alternative for the detection of cancer biomarkers in blood samples. Such alternatives play a crucial role in the context of patients with a high risk of developing cancer and who cannot undergo a tissue biopsy.
By End Use
The end-user segment comprises hospitals and clinics, diagnostic centers, research, and academic institutes, and others. The diagnostic centers segment contributed the largest shares to the market growth in 2022. The increased demand for CTC testing in diagnostic centers for screening of cancer in high-risk populations supports the segmental growth in terms of access to personalized and effective cancer care. Moreover, the research and academic institutes segment is also estimated to contribute substantial shares to the market growth during the forecast period. The demand for CTCs to provide insights into the biology of cancer, including how cancer cells spread and metastasize supports the deployment of CTCs in research and academic institutes for the purpose of providing information about tumor heterogeneity used for developing personalized treatment strategies.
The regional segment comprises North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. North America contributed the largest shares to the market growth in 2022. The well-developed healthcare infrastructure, including advanced diagnostic and treatment facilities, supports the development and adoption of new technologies such as CTC analysis in the North American region. Moreover, rising expenditures in the development of new cancer technologies by cancer research institutions for improved cancer detection and treatment also fuel the market expansion in the region.
Further, Asia Pacific is also anticipated to contribute substantial shares to the market growth during the forecast period. The presence of established regulatory frameworks by government in terms of favorable development and adoption of new medical technologies supports the growth of the CTCs market in the Asia Pacific region.
Circulating tumor cells Market Competitive Landscape:
The market for circulating tumor cells (CTCs) is highly competitive and rapidly evolving. The usage of CTCs as a non-invasive biomarker for cancer diagnosis and monitoring has led to the development of a range of innovative technologies and products by major market players. A large number of startups and early-stage companies are also entering the CTC market to gain a competitive market position along with established players by developing new technologies and products for cancer diagnosis and monitoring. Thus, the competition in the CTC market is expected to intensify in the forecast period due to the increased demand for non-invasive cancer diagnostics. Mentioned are market players currently comprising the market concentration–
• Fluxion Biosciences Inc.
• Precision Medicine Group, LLC.
• Aviva Systems Biology Corporation
• BIOCEPT, Inc.
• Thermo Fisher Scientific
• Greiner Bio One International GmbH
• Ikonisys Inc.
• Miltenyi Biotec
• Canopus Bioscience Ltd.
• Biolidics Limited
• Creativ MicroTech, Inc.
• LungLife AI, Inc.
• Epic Sciences
• Rarecells Diagnostics
• Menarini Silicon Biosystems
• LineaRx, Inc. (Vitatex, Inc.)
• Sysmex Corporation
• STEMCELL Technologies, Inc.
• Cynvenio Biosystems
• In October 2020, LungLife AI, a leader in the diagnosis and management of liquid biopsy technology for cancer, stated that the clinical data related to the research collaboration in the early detection of lung cancer is anticipated to be published publically at the International Association for the Study of Lung Cancer (IASLC) Hot Topic Meeting.
• In February 2021, Bio-Techne Corporation announced that the Bio-Techne brand called Exosome Diagnostics published a research paper named Exosome-based Liquid Biopsies in Cancer: Opportunities and Challenges (Yu, W et al.). The study was published in the high-rated peer-reviewed journal named the Annals of Oncology which provides unique insights about liquid biopsies comprising CTC analysis and cfDNA.
• In December 2021, Rarecells, Inc., a renowned Liquid Biopsy business that specializes in non-invasive tests for early diagnosis of cancer, announced the closing of a USD 5 Million financial arrangement that helped the business in scoring total Series A funding of USD 13 Million. The funds are expected to support the start of clinical operations and laboratory in the United States which is focused on early detection tests of Prostate Cancer and Acute Myeloid Leukemia.